Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

ClinicalTrials.gov ID: NCT04960618

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04960618. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Pembrolizumab in Combination With Gemcitabine for Previously Treated Mycosis Fungoides and Sézary Syndrome: Efficacy and Characterization of Immune Response

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.

Study identification

NCT ID
NCT04960618
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
14 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 1, 2021 (Actual)
Primary completion
Jul 2027 (Estimated)
Completion
Jul 2027 (Estimated)
Last update posted
Nov 2, 2026

2021 – 2027

United States locations

U.S. sites
8
U.S. states
2
U.S. cities
7
Facility City State ZIP Site status
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge New Jersey 07920 —
Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey 07748 —
Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey 07645 —
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) Commack New York 11725 —
Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York 10604 —
Memorial Sloan Kettering Cancer Center (All protocol activities) New York New York 10021 —
Columbia University New York New York 10032 —
Memorial Sloan Kettering Nassau (Limited protocol activities) Uniondale New York 11553 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04960618, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 2, 2026 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.